Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus’ replication
Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...
Lenacapavir, a long-acting injectable PrEP, requires two injections annually, marking a significant advancement in HIV ...
Dr Robert Mutumba, the head of the Aids Control Programme at the Ministry of Health, told Daily Monitor that Ugandans are ...
6don MSN
KZN Health MEC warns that HIV prevention drug Lenacapavir is 'not a licence for risky behaviour'
Lenacapavir, a long-acting injectable form of HIV prevention, is set to revolutionise HIV prevention strategies in South ...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses ...
The U.S. Food and Drug Administration (FDA) recently approved a groundbreaking new option for preventing HIV, the virus that causes AIDS. The injectable drug lenacapavir was approved in June and is ...
A study suggests twice-yearly Yeztugo offers HIV prevention without adversely affecting gender-affirming care.
A phase 2 randomized study evaluating the efficacy and safety of once-weekly oral islatravir plus lenacapavir (ISL+LEN) in ...
Once-daily oral treatments for HIV-1 infection are effective, but they can create medication compliance challenges. In an open-label phase II study, a similarly high proportion of patients randomized ...
– Positive Phase 3 Results from Both ARTISTRY-2 and ARTISTRY-1 Trials will Form the Basis of Regulatory Submissions – Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from ...
In 2026, AI will continue threading itself into behavioral health, and the bar will rise sharply for what counts as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback